Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
ALCLS says it is shifting focus to in vivo gene editing and advancing HEAL-101 and HEAL-201 for severe lipid disorders, while discontinuing internal cell therapy programs and extending cash runway into 2028.
ALCLS announced a shift to in vivo gene editing, advancing HEAL-101 and HEAL-201 for severe lipid disorders and extending its cash runway into 2028, while discontinuing internal cell therapy programs.